APEPTICO Announces Successful Completion of Phase I Trial with AP301 in Oedematous Respiratory Failure
APEPTICO GmbH, a biotechnology company developing peptide drugs based on its PEPBASE(TM) discovery technology, today ann…
APEPTICO GmbH, a biotechnology company developing peptide drugs based on its PEPBASE(TM) discovery technology, today ann…
APEPTICO, a privately-held biotechnology company developing peptide drugs based on its PEPBASE(TM) discovery technology,…